Pixium Vision
Develops retinal implant systems for patients who have lost their eyesight.
Launch date
Employees
Market cap
AUD2.6m
Enterprise valuation
AUD34m (Public information from Feb 2024)
Share price
€0.3764 PIX.PA
Company register number 538797655
Paris Île-de-France (HQ)
Financials
Estimates*
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 2.0m | 2.0m | 2.0m | 3.0m | 2.0m | 2.0m | 1.0m |
| % growth | - | - | - | 50 % | (33 %) | - | (50 %) |
| EBITDA | (6.0m) | (8.0m) | (7.0m) | (10.0m) | (11.0m) | (10.6m) | 5.5m |
| % EBITDA margin | (300 %) | (400 %) | (350 %) | (333 %) | (550 %) | (530 %) | 550 % |
| Profit | (14.0m) | (10.0m) | (9.0m) | (11.0m) | (10.0m) | (12.4m) | 3.4m |
| % profit margin | (700 %) | (500 %) | (450 %) | (367 %) | (500 %) | (620 %) | 340 % |
| EV / revenue | 14.2x | 8.9x | 16.2x | 14.4x | 4.6x | 9.9x | 26.9x |
| EV / EBITDA | -4.7x | -2.2x | -4.6x | -4.3x | -0.8x | -1.9x | 4.9x |
| R&D budget | 2.0m | - | - | - | - | - | - |
| R&D % of revenue | 100 % | - | - | - | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
* | N/A | Support Program | |
€15.0m | Series A | ||
| N/A | €34.5m Valuation: €100m | IPO | |
* | €11.0m | Post IPO Debt | |
€6.2m | Post IPO Equity | ||
* | N/A | Post IPO Equity | |
€7.3m Valuation: €20.8m 10.4x EV/LTM Revenues -2.6x EV/LTM EBITDA | Secondary | ||
* | €1.8m | Post IPO Debt | |
| Total Funding | AUD25.5m | ||
Related Content
Recent News about Pixium Vision
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.